rmhTNF聯(lián)合順鉑腔內(nèi)注射治療惡性漿膜腔積液的臨床觀察

陳劍波

【摘要】 目的：評(píng)價(jià)重組改構(gòu)人腫瘤壞死因子（rmhTNF）聯(lián)合順鉑治療惡性漿膜腔積液的療效、安全性和對(duì)患者生活質(zhì)量的影響。方法：選取2011年8月-2015年7月筆者所在醫(yī)院腫瘤內(nèi)科收住院的符合本研究標(biāo)準(zhǔn)的中晚期惡性腫瘤合并惡性漿膜腔積液的患者83例，采用信封法隨機(jī)抽取分為兩組，試驗(yàn)組38例，對(duì)照組45例。試驗(yàn)組抽取漿膜腔積液后腔內(nèi)灌注順鉑50 mg/m2及rmhTNF 150萬(wàn)單位，對(duì)照組抽取漿膜腔積液后采用順鉑50 mg/m2單藥灌注。觀察比較兩組患者的臨床療效、不良反應(yīng)及生活質(zhì)量。結(jié)果：試驗(yàn)組治療有效率為84.2%（32/38），高于對(duì)照組的64.4%（29/45），比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；試驗(yàn)組患者治療后1周KPS評(píng)分較治療前均明顯改善，比較差異均有統(tǒng)計(jì)學(xué)意義（P<0.05）；不良反應(yīng)發(fā)生率與對(duì)照組比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論：rmhTNF聯(lián)合順鉑腔內(nèi)注射治療惡性漿膜腔積液可取得更加滿意的療效，有效提高疾病控制率，改善患者生活質(zhì)量，值得臨床推廣。

【關(guān)鍵詞】 惡性漿膜腔積液； 腫瘤； 重組改構(gòu)人腫瘤壞死因子； 聯(lián)合

doi：10.14033/j.cnki.cfmr.2017.32.002 文獻(xiàn)標(biāo)識(shí)碼 A 文章編號(hào) 1674-6805（2017）32-0004-03

Clinical Observation of rmhTNF and Cisplatin in the Treatment of Malignant Serous Effusion/CHEN Jianbo.//Chinese and Foreign Medical Research，2017，15（32）：4-6

【Abstract】 Objective：To evaluate the efficacy and safety of recombinant human tumor necrosis factor （rmhTNF）and its effect on the quality of life of patients.Method：From August 2011 to July 2015，83 patients with advanced malignant neoplasm associated with malignant serous effusion admitted to our hospital for oncology were randomly divided into two groups according to the envelope method，38 in the experimental group and 45 in the control group.Patients in the experimental group were perfused with 50 mg/m2 of Cisplatin and 1.5 million units of rmhTNF；patients in the control group were perfused with 50 mg/m2 of Cisplatin.The therapeutic effect，adverse reactions and quality of life were observed and compared between the two groups.Result：The effective rate of the treatment group was 84.2%（32/38），which was higher than 64.4%（29/45） of the control group，the difference was statistically significant（P<0.05）.The KPS score of the experimental group was significantly improved 1 week after treatment compared with before treatment，the difference was statistically significant（P<0.05）；there was no significant difference in the incidence of adverse reactions between the two groups（P>0.05）.Conclusion：rmhTNF combined with cisplatin in the treatment of malignant serous effusion can achieve more satisfactory curative effect，effectively the disease control rate and improve quality of life of patients，worthy of clinical promotion.

【Key words】 Malignant serous effusion； Cancer； rmhTNF； Combination

First-authors address：The First Affiliated Hospital of Xiamen University，Xiamen 361003，China

惡性漿膜腔積液是惡性腫瘤晚期患者常見(jiàn)的嚴(yán)重并發(fā)癥之一，臨床上常反復(fù)出現(xiàn)，難以根治，如能有效控制，對(duì)于提高該類患者的生活質(zhì)量從而延長(zhǎng)生存期有著重大意義。目前臨床上普遍采用穿刺置管引流等手段以減輕痛苦、緩解癥狀。選取筆者所在醫(yī)院2011年8月-2015年7月應(yīng)用重組改構(gòu)人腫瘤壞死因子（rmhTNF）聯(lián)合順鉑治療惡性漿膜腔積液的患者，評(píng)價(jià)該治療方法的療效、安全性和對(duì)患者生活質(zhì)量的影響情況，現(xiàn)報(bào)道道如下。endprint